Q-omics provides the consensus-scored NAXE profile across patient tissues and cancer cell-line models. NAXE expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, NAXE is differentially expressed in 16, with the highest sampling consensus in LUAD. Additionally, NAXE protein abundance shows 21,621 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight UVM, LUAD, and LSCC as cancer lineages where NAXE shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NAXE — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NAXE survival associations across molecular data types. NAXE RNA expression shows survival associations in the most cancer types (28), followed by mutation status (3) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NAXE RNA expression–survival associations across cancer types. High NAXE expression shows unfavorable associations in UVM, ACC, KIRP, KICH, SKCM and LAML. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for NAXE RNA expression.
This table summarizes NAXE tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16, while mass-spec protein shows differences in 6. The strongest signals are observed in LUAD for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for NAXE. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NAXE shows higher tumor expression in LUAD, HNSC, BLCA, LIHC, COAD and LUSC. The LUAD box plot shows higher NAXE RNA expression in tumor versus normal tissue (log2 FC = +1.654, t-test p < 0.001).
This table shows molecular features associated with NAXE in patient tissues and cancer cell lines. In patient samples, NAXE shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, NAXE RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in SKIN and UPPER_AERODIGESTIVE_TRACT.
